在类风湿性关节炎中,治疗结果按干扰素概况和自身抗体分层
Shoichi Fukui1, Tohru Michitsuji2, Yushiro Endo1
1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Journal of autoimmunity
|September 30, 2025
概括
包括类风湿因子和特定IFN-γ/IFN-α2水平在内的干扰素概况可以预测类风湿关节炎治疗的成功. 这种方法有助于选择个性化疗法,特别是IL-6抑制剂,以提高患者的缓解率.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 个性化医疗是个性化的医疗.
背景情况:
- 风湿性关节炎 (RA) 治疗的进步仍然使一些患者在使用常规疗法时没有缓解.
- 预测RA治疗反应的生物标志物对于个性化治疗策略至关重要.
研究的目的:
- 调查干扰素概况和自身抗体是否可以预测类风湿性关节炎患者的治疗结果.
- 确定与RA成功缓解相关的免疫标志物.
主要方法:
- 对接受生物/向合成DMARD治疗的200名类风湿性关节炎患者的前性评估.
- 对干扰素 (IFN) 概况 (IFN-γ,IFN-α2) 和自身抗体的分析,包括类风湿因子和抗碳amylated 蛋白 IgM.
- 免疫学标志物与治疗缓解率之间的相关性分析.
主要成果:
- 在风湿因子和IFN-γ水平之间发现了显著的正相关性.
- 具有高IFN-γ/低IFN-α2配置文件的患者表现出更高的缓解率.
- 在响应者中观察到明显的免疫聚类模式和升高的B细胞刺激细胞因子.
- 在高IFN-γ/低IFN-α2组中,观察到对IL-6抑制剂的优异反应率.
- 在患者组之间观察到抗碳amylated 蛋白质IgM抗体的显著差异.
结论:
- 干扰素分析,与自身抗体分析一起,作为预测RA治疗反应的实际查方法.
- 这种方法促进了个性化治疗选择,有可能改善RA患者的缓解率.
- 识别特定的干扰素配置文件可以指导针对性治疗的选择,如IL-6抑制剂,以获得最佳的结果.
相关概念视频
Autoimmune Disorders
1.5K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493


